Professional Documents
Culture Documents
HORMONAL REGULATION II
Dr. Suzette M. Mendoza | March 05, 2019 LE5 TRANS3
Cell secretion
Insulin secreted from cells Islet of Langerhans
Glucagon secreted from cells in Islets of Langerhans
Type of Receptor
Insulin: Receptor Tyrosine Kinases
Glucagon: GPCR
II. INSULIN
Major anabolic hormone
Insulin signaling system coordinates systemic growth
Released from the β-cells of the pancreas in response to
carbohydrate ingestion, promotes glucose utilization as a fuel
and glucose storage as fat and glycogen[2021A trans]
At molecular levels insulin regulates many pathways
Glycolysis and glucose storage (muscle and liver)
Inhibits ketogenesis and gluconeogenesis (liver)
Lipid synthesis and storage (liver)
Stimulation of protein synthesis (muscle and liver)
Insulin increases as blood glucose level rises
~30-45 minutes after a high carbohydrate meal intake (well- Figure 2. a) Insulin synthesis b) mature insulin
fed nutritional stage)
Insulin decreases as blood glucose level diminishes Preproinsulin
Glucose is absorbed and stored or utilized by tissues MW: 11,500 kD
Blood glucose return to basal level (~120 minutes after Pre or leader sequence
meal) 23 hydrophobic amino acids (core hydrophobic amino
acids) that direct the molecule into the cisternae of ER
Metabolic effects: Proinsulin
Carbohydrate Metabolism MW: 9,000 kD
Increasing glucose uptake in skeletal muscles & adipocytes by Provides the conformation for the proper location of the
enhancing GLUT4 on the PM disulfide (S-S) bridges
Decrease Gluconeogenesis Sequence: B chain – C (connecting) peptide – A chain
Lipid Metabolism Mature Insulin
Increased lipid synthesis in liver & adipocytes (via SREBP) Composed of an A chain and a B chain linked by 3 disulfide
Decreasing FA release from TAGs in adipocytes & muscles bridges
Protein Metabolism C-peptide is representative of mature insulin since they are
Increase protein synthesis secreted together
Decrease protein degradation C-peptide can be used in tests to measure insulin since
insulin has a very short half-life
A. STRUCTURE OF INSULIN Modification:
Signaling sequence cleaved in ER
C-Peptide cleaved in Golgi apparatus
Degradation of Insulin
Since insulin is a polypeptide hormone, it can be degraded by
denaturation or cleavage of peptide bonds
Enzyme: insulinase
Site: primarily in the liver and to a lesser extent in the kidneys and
skeletal muscles
C. REGULATORS OF INSULIN RELEASE
Glucose levels in the pancreas stimulate insulin release.
Increased glucose levels or hyperglycemia are the major
stimulating factors of insulin release
Only insulin & glucagon are synthesized and released in direct
response to changing levels of sugar in the blood.
Threshold for insulin release: 80 mg%
Figure 1. Structure of human insulin Proportional to glucose concentration up to 300 mg%
D. RELEASE OF INSULIN
E. ACTION OF INSULIN
First Phase
Insulin is released from the pancreas in a biphasic manner
First phase is a brief spike (immediately after eating) in
insulin followed by a post prandial plateau (hours)
Immediate response to increased blood glucose levels
First phase response involves release of pre-formed insulin
ATP-Gated K+ Channels
Molecular target of sulfonylurea (anti-diabetic drug)
Closes when sulfonylurea is present and causes insulin
release
K. REGULATION OF INSULIN SIGNALING CASCADE Figure 8. Insulin Signaling Pathway Termination. Orange circles are shown to
inhibit their respective pathways.
Serine-threonine kinases
Phosphorylates and inhibits IRS 1-4, no phosphorylation of II. CLINICAL CORRELATIONS
activated insulin receptor A. OVERVIEW OF INSULIN DEFICIENCY/RESISTANCE
Negative feedback mechanism on the signaling pathway via Can be categorized based on site of resistance:
serine phosphorylation of IRS by interfering with functional Pre-receptor
domains of IRS Possible defect
Protein phosphatase 2A (PP2A) insulin receptor (IR)
Inhibition of MAP kinase pathway antibodies (type B insulin resistance)
Key negative regulator of PI3K/Akt pathway by abnormal molecule
dephosphorylation and inactivation of Akt/PKB and PKCλ Rare
Phosphotyrosine phosphatase 1B (PTP1B) Receptor
Interacts directly with IR and dephosphorylates tyrosine Possible defect: decrease in the number or affinity of IR
residues leading to decreased activity Common is obese patients (happens in their adipocytes)
Termination of insulin action Post-receptor
Phosphatase and Tensin homologue on chromosome 10 Possible defect: defects in signal transduction (e.g.
(PTEN) defective tyrosine phosphate, mutations in genes coding for
3’ phosphatase that converts PIP3 to PIP2 IRS-1 and PI-3K, defective translocation of GLUT4,
Suppresor of Cytokines (SOCS) and Growth factor-receptor- increase in fatty acids)
bound protein 10 (Grb10) Post-receptor resistance is the most common type of
Down-regulate IR function by dephosphorylation of IR and its insulin resistance
substrates B. TYPE I DIABETES MELLITUS
SOCS might induce ubiquitin-mediated degradation of IRS1 Lack of insulin release due to destruction of islet β cells of the
and IRS2 pancreas
SRC homology 2 (SHIP) Pathophysiology of Type I DM:
Degrades PIP2 and PIP3 The lack of insulin leads to two lines of effects
SHIP1 has a 3’ phosphatase activity Increase gluconeogenesis and decrease glucose uptake
SHIP2 has a 5’ phosphatase activity hyperglycemia glycosuria osmotic diuresis
SH2-domain containing tyrosine phosphatase 2 (SHP2) dehydration (can be fatal)
Dephosphorylate other phosphotyrosines that mediate Increase lipolysis increase ketogenesis ketonemia
binding of PI3K and Grb2 ketonuria and metabolic acidosis metabolic
Insulin degrading enzyme (IDE) acidosis leads to compensatory hyperventilation
Promotes degradation of insulin Onset is usually at earlier years of age because the infections
Internalization of insulin-insulin receptor complex into that cause Type I DM usually occur early in life (e.g. viral
endosomes infections)
Termination of insulin signaling See Table 5 for a tabulated comparison between Type I and II
DM.
C. TYPE II DIABETES MELLITUS
Due to impaired β cell function and decrease in the
sensitivity of the receptors for insulin
Insulin synthesis is active but the receptors are unresponsive
Will initially cause hyperinsulinemia (overproduction of insulin)
to try to compensate for the lack of unresponsiveness
However, β cells will eventually be burned out and slow down
production of insulin increased gluconeogenesis
There is also hyperglycemia toxicity which can cause β cell
destruction
Patient characteristics:
Have high BP (140/90 mmHg or greater)
III. GLUCAGON
Major counter-insulin or counter-regulatory polypeptide hormone
that is secreted in fasting and starvation state where blood
glucose is low
Stimulation of:
Mobilization of fuel reserves
Fuel reserves utilized: liver glycogen during the first 24
hours, muscle glycogen for muscle use ONLY, and infinite
number of TAGs from adipocytes
Glycogenolysis
Gluconeogenesis
Glucose is available to glucose-dependent tissues in between Figure 12. Synthesis of Glucagon from Preproglucagon
meals
C. STRUCTURE OF GLUCAGON
Target organs: Liver (major) and adipocytes
Single polypeptide chain of 29 amino acids
No glucagon receptor in skeletal muscles
VI. REFERENCES
2021A Trans
Lecturer’s ppt
Bayne’s Clinical Biochemistry. 4th edition
Lieberman, M. (2018). Mark’s Medical Biochemistry: A Clinical Approach 5th
edition
Rodwell, V., et.al. Harper’s Illustrated Biochemistry 30th edition